| . | Healthy control (n = 15) . | DNASE1L3 deficient (n = 4) . | SLE renal (n = 87) . | SLE nonrenal (n = 33) . | Anti-Ro+ (n = 45) . |
|---|---|---|---|---|---|
| Demographics | |||||
| Female, n (%) | 12 (80) | 2 (50) | 75 (87) | 31 (94) | 45 (100) |
| Age (yr), median (IQR) | 36 (23–59)a | 9 (7–14) | 3–7 (20-78) | 39 (27–80) | 35 (27–64) |
| Race/ethnicity, n (%) | |||||
| Hispanic/Latino | 0 | 0 | 25 (29) | 16 (48) | 0 |
| Non-Hispanic/Latino | 0 | 0 | 53 (61) | 17 (52) | 0 |
| White | 5 (33) | 4 (100) | 38 (44) | 23 (70) | 38 (84) |
| Black | 5 (33) | 0 | 27 (31) | 7 (21) | 1 (2) |
| Asian | 1 (7) | 0 | 21 (24) | 2 (6) | 3 (7) |
| Other | 1 (7) | 0 | 2 (2) | 1 (3) | 2 (4) |
| Not reported | 3 (20) | — | — | — | 1 (2) |
| Readoutsb | |||||
| DNASE1L3 activity, % | 100 (89–100.5, n = 15) | 0 (n = 4) | 68 (62–100, n = 37) | 92 (85–100, n = 14) | 100 (85–100, n = 15) |
| Anti-DNASE1L3 ELISA, OD | 0.15 (0.13–0.26, n = 15) | — | 0.40 (0.26–0.80, n = 40) | 0.30 (0.23–0.36, n = 18) | 0.19 (0.13–0.25, n = 18) |
| cfDNA total, ng/ml | 5.6 (3.2–8.4, n = 15) | 10.0 (9.0–17.6, n = 4) | 6.3 (3.4–11.8, n = 44) | 5.4 (2.6–10.2, n = 15) | 17.2 (6.5–26.5, n = 15) |
| MP cfDNA fraction, % | 23 (19–35, n = 15) | 70 (40–83, n = 4) | 62 (39–73, n = 44) | 33 (26–46, n = 15) | 49 (43–60, n = 15) |
| DNASE1L3-sensitive binding to MPsc | 0 (0%, n = 15) | 3 (75%, n = 4) | 50 (57%, n = 87) | 5 (15%, n = 33) | 3 (7%, n = 45) |
| . | Healthy control (n = 15) . | DNASE1L3 deficient (n = 4) . | SLE renal (n = 87) . | SLE nonrenal (n = 33) . | Anti-Ro+ (n = 45) . |
|---|---|---|---|---|---|
| Demographics | |||||
| Female, n (%) | 12 (80) | 2 (50) | 75 (87) | 31 (94) | 45 (100) |
| Age (yr), median (IQR) | 36 (23–59)a | 9 (7–14) | 3–7 (20-78) | 39 (27–80) | 35 (27–64) |
| Race/ethnicity, n (%) | |||||
| Hispanic/Latino | 0 | 0 | 25 (29) | 16 (48) | 0 |
| Non-Hispanic/Latino | 0 | 0 | 53 (61) | 17 (52) | 0 |
| White | 5 (33) | 4 (100) | 38 (44) | 23 (70) | 38 (84) |
| Black | 5 (33) | 0 | 27 (31) | 7 (21) | 1 (2) |
| Asian | 1 (7) | 0 | 21 (24) | 2 (6) | 3 (7) |
| Other | 1 (7) | 0 | 2 (2) | 1 (3) | 2 (4) |
| Not reported | 3 (20) | — | — | — | 1 (2) |
| Readoutsb | |||||
| DNASE1L3 activity, % | 100 (89–100.5, n = 15) | 0 (n = 4) | 68 (62–100, n = 37) | 92 (85–100, n = 14) | 100 (85–100, n = 15) |
| Anti-DNASE1L3 ELISA, OD | 0.15 (0.13–0.26, n = 15) | — | 0.40 (0.26–0.80, n = 40) | 0.30 (0.23–0.36, n = 18) | 0.19 (0.13–0.25, n = 18) |
| cfDNA total, ng/ml | 5.6 (3.2–8.4, n = 15) | 10.0 (9.0–17.6, n = 4) | 6.3 (3.4–11.8, n = 44) | 5.4 (2.6–10.2, n = 15) | 17.2 (6.5–26.5, n = 15) |
| MP cfDNA fraction, % | 23 (19–35, n = 15) | 70 (40–83, n = 4) | 62 (39–73, n = 44) | 33 (26–46, n = 15) | 49 (43–60, n = 15) |
| DNASE1L3-sensitive binding to MPsc | 0 (0%, n = 15) | 3 (75%, n = 4) | 50 (57%, n = 87) | 5 (15%, n = 33) | 3 (7%, n = 45) |
Continuous variables are given as median (interquartile range [IQR]), and categorical variables are given as number of cases (%).
The age of one control subject was unknown and was not included in the calculation.
Not all patients in every group were tested for all readouts. The n in each of the readouts refers to the number of patients from that group who were tested for this readout.
Table 1 shows DNASE1L3-sensitive binding at the time cfDNA and plasma activity of DNASE1L3. Fig. 6 G shows the number of patients with DNASE1L3-sensitive binding at any time point.